Walnut, CA—Farlong Pharmaceutical has completed a three-year clinical trial to determine the effects of Farlong NotoGinseng, according to a press release.

The randomized, placebo-controlled, double-blind, parallel study was performed on 100 adults between December 2016 and June 2019. It sought to determine the effect of Farlong’s brandedPanax notoginsengextract on cholesterol and blood pressure.
Related: Keys to a Healthy Heart Herbs & Botanicals: Trends, Safety, and Traceability Study: Apples May Support Heart Health
Over a 12 week period, the participants were given one serving of the product or the placebo to take orally at the same time every day, 30 minutes before a meal, for 84 days. From baseline to week eight, the NotoGinseng group saw a significant decrease in serum low-denisty lipoprotein (LDL) cholesterol, the ‘bad’ cholesterol. Following 12 weeks of supplementation, the test group saw a slight increase in high-density lipoprotein (HDL) cholesterol, the ‘good’ cholesterol. The test group also saw decreases in both systolic and diastolic blood pressures.

The placebo group, in comparison, had a decrease in HDL cholesterol, and saw increases in systolic and diastolic blood pressures.

The press release notes: “Even a small reduction in blood pressure is clinically meaningful in populations at risk for developing cardiovascular diseases.”